THE EFFECTIVENES OF COMPLEX DRUG “BIFIDUM BAG” FOR STATUS CORRECTION OF LARGE INTESTINE MICROBOICENOSIS AND ANTIOXIDANT PROPERTIES OF COLONOCYTES IN EXPERIMENTAL DYSBIOSIS

Cover Page

Cite item

Full Text

Abstract

The effectiveness of complex drug “Bifidum BAG” for status correction of large intestine microbiocenosis and antioxidant properties of colonocytes in experimental dysbiosis has been studied. Acomplex drug was administered to experimental animals, which includes Bifidobacterium and Dihydroquercetin. Quantitative and qualitative study of large intestine was done in mices by bacteriological method. The state of lipid peroxidation system was evaluatedaccoding to the content of acylhydroperoxide and malonic dialdehyde. The state of antioxidant protective system was reached by means of catalase and superoxide dismutase activity. Experimental dysbiosis was shown as significant changes in mucosal microflora, changes colonocytes antioxidant properties. The use of the complex preparation “Bifidum BAG”, led to the normalization of the colon microbiota (11 of 16 microorganisms were recovered). After correction gentamicin-associated dysbiosis with a complex probiotic, a positive effect of the drug on the colonocytes antioxidant defense was noted. So the activity of catalase increased 1.1 times, compared with the determined index in the group “dysbiosis”. The activity of superoxide dismutase increased 2 times in comparison with the group “dysbiosis”, exceeding the value of the control group. The concentration of LPO products in colonocytes of experimental animals decreased significantly. The content of malonicdialdehyde and acylhydroperoxide decreased 1.6 times and 5.6 times in comparison with the determined index of the group “dysbiosis”, respectively.

About the authors

O. A. Medvedeva

Kursk State Medical University

Author for correspondence.
Email: nataliverev@ya.ru
Kursk, Russia

V. A. Korolev

Kursk State Medical University

Email: nataliverev@ya.ru
Kursk, Russia

N. A. Verevkina

Kursk State Medical University

Email: nataliverev@ya.ru
Kursk, Russia

V. A. Riadnova

Kursk State Medical University

Email: nataliverev@ya.ru
Kursk, Russia

References

  1. Xu J., Lian F., Zhao L. Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula. ISME J. 2015. № 9. P. 552-562.
  2. Jiang W., Wu N., Wang X. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep. 2015. № 5. P. 1-7.
  3. Berbers R.M., Nierkens S., Van Laar J.M. Microbial dysbiosis in common variable immune deficiencies: evidence, causes, and consequences. Trends Immunol. 2017. № 38. P. 206-216.
  4. Omarova L.A., Omarov T.R. An intestinal dysbacteriosis as a side effect of anti-helicobacter therapy. Sechenovsky Vestnik. 2014. № 3 (17). P. 55-58.
  5. Forbes J.D., Van Domselaar G., Bernstein C.N. The gut microbiota in immune-mediated inflammatory diseases. Front. Microbiol. 2016 7:1081. 10.3389.
  6. Kamada N., Seo S.U., Chen G.Y. (2013) Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol. 2013. № 13. P. 321-335.
  7. Skrypnik K., Bogdanski P., Loniewski I., Reguta J., Suliburska J. Effect of probiotic supplementation on liver function and lipid status in rats. Acta Sci Pol Technol Aliment. 2018. № 2. Р. 185-192.
  8. Ilyenko L.I., Xolodova I.N. Intestinal dysbiosis in children. Medical matter. 2008. № 2. P. 3-13.
  9. Gapon M.N. Indicators of antioxidant protection of the body with experimental intestinal dysbacteriosis, caused by the use of a broad-spectrum antibiotic: PhD Thesis. Rostov-on-Don, 2007. P. 153.
  10. Coelho O.G.L., Cândido F.G., Alfenas R.C.G. Dietary fat and gut microbiota: mechanisms involved in obesity control. Crit Rev Food Sci Nutr. 2018. № 31. P. 1-30.
  11. Joossens M., Huys G., Cnockaert M. Dysbiosis of the faecalmicrobiota in patients with Crohn’s disease and their unaffected relatives. Gut. 2011. № 5. P. 631-637.
  12. Baba Y., Iwatsuki M., Yoshida N., Watanabe M., Baba H. Review of the gut microbiome and esophageal cancer: Pathogenesis and potential clinical implications. Ann Gastroenterol Surg. 2017. № 2. Р. 99-104.
  13. Baylina E.E., Xomchenko T.V., Myrnachev G.P. On the circulation of pathogenic leptospirae. Pacific Medical Journal. 2010. № 4. P. 91.
  14. Horspool A.M., Chang H.C. Neuron-specific regulation of superoxide dismutase amid pathogen-induced gut dysbiosis. Redox Biol. 2018. Р. 377-385.
  15. Kashkin K.P., Karaev Z.O. Immune reactivity of the body and antibiotic therapy. L.: Medicine, 1984. P. 200.
  16. Bogdanova N.A., Nesvizcky U.V., Vorobyev A.A. Study of the parietal microflora of the gastrointestinal tract of rats with oral administration of probiotic preparations. Messenger RAMN. 2006. № 2. P. 6-10.
  17. Vorobyev A.A. et al. Features of microbiocenosis of parietal mucin of the gastrointestinal tract of rats. Journal of Microbiology Epidemiology and Immunobiology. 2005. № 6. P. 3-7.
  18. Nesvizcky U.V. et al. Microbiocenosis of parietal mucin of the gastrointestinal tract of rats with induced dysbiosis. Journal of Microbiology Epidemiology and Immunobiology. 2007. № 3. P. 57-60.
  19. Makarenko E.V. Complex determination of the activity of superoxide dismutase and glutathione reductase in erythrocytes of patients with chronic liver diseases. Laboratory work. 1988. № 11. P. 48-50.
  20. Koroluk M.A. et al. Method for determination of catalase activity. Laboratory work. 1988. № 1. P. 16-19.

Copyright (c) 2019 Medvedeva O.A., Korolev V.A., Verevkina N.A., Riadnova V.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies